RxDoctor Payments DataLook up a doctor →

William Fitzgibbons, MD

Family Medicine · Elkhorn, NENPI 1265405617

Payments from drug & device makers

$6,977,890in general payments, 2019–2025

Across 1,553 payments — averaging $4493.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$5.8M
  • Merck$342K
  • Boehringer Ingelheim$303K
  • Abbott$215K
  • Genentech, Inc.$111K
  • Regeneron$87K
  • plus $125K from 51 others
$815in research payments, 2019–2025

Across 10 payments — averaging $81.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$815

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.605$5,794,528
Merck35$341,853
Boehringer Ingelheim75$303,361
Abbott27$215,259
Genentech, Inc.52$111,249
Regeneron33$87,024
AstraZeneca74$60,796
Pfizer42$21,858
Boehringer Ingelheim International GmbH107$17,419
Novo Nordisk AS6$9,172
Seqirus USA Inc3$5,540
Novo Nordisk76$1,180
AbbVie(2 entities)69$1,035
Eli Lilly1$1,000
Amgen41$941
Lilly USA, LLC48$797
GSK56$712
Bayer22$494
Johnson & Johnson(2 entities)25$481
Corcept Therapeutics16$433
Otsuka America Pharmaceutical, Inc.11$305
Jazz Pharmaceuticals Inc.11$266
Amarin Pharma, Inc.14$240
Biohaven Pharmaceuticals, Inc.12$210
Biohaven Pharmaceutical Holding Company Ltd.4$174
Grifols USA, LLC6$119
Novartis7$116
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$111
Xeris Pharmaceuticals, Inc.6$105
Takeda Pharmaceuticals U.S.A., Inc.7$104
Philips North America LLC5$100
Astellas Pharma Global Development2$84
Actelion Pharmaceuticals US, Inc.4$82
Eisai Inc.5$79
Idorsia Pharmaceuticals US Inc2$74
Kowa Pharmaceuticals America, Inc.5$72
E.r. Squibb & Sons, L.L.C.4$59
Sanofi Pasteur Inc.3$51
Genentech USA, Inc.3$46
Teva Pharmaceuticals USA, Inc.2$37
Ultragenyx Pharmaceutical Inc.2$35
Itamar Medical Inc1$26
Sumitomo Pharma America, Inc.2$25
Ironwood Pharmaceuticals, Inc1$22
Esperion Therapeutics, Inc.1$19
Edwards Lifesciences1$19
Mylan Specialty L.p.1$18
Sanofi-aventis U.S. LLC1$18
Astellas Pharma US Inc1$18
Exact Sciences1$16
Nalpropion Pharmaceuticals LLC1$16
Lundbeck LLC1$16
Nestle Healthcare Nutrition Inc.1$16
Ironshore Pharmaceuticals Inc.1$15
Hologic Sales And Service, LLC1$15
VBI Vaccine (delaware) Inc.1$14
Forte Bio-pharma LLC1$14

How this compares

$6,977,890 in reported general payments places this provider in the 95th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$107,605
Medicare patients
276
Services billed
1,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Elkhorn

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →